Xiaoli Cheng

Title: Innovations of Xiaoli Cheng in Autoimmune Inflammation Treatment

Introduction

Xiaoli Cheng is a prominent inventor based in Mountain View, CA (US), known for her significant contributions to the field of autoimmune inflammation treatment. With a total of 8 patents to her name, she has made remarkable strides in developing peptide inhibitors that target the interleukin-23 receptor.

Latest Patents

Among her latest patents are compositions of peptide inhibitors of the interleukin-23 receptor. This invention relates to compositions that include peptide inhibitors or their pharmaceutically acceptable salt or solvate forms. These compositions are designed for the treatment of autoimmune inflammation and related diseases and disorders. Another notable patent involves oral peptide inhibitors of the interleukin-23 receptor, which are used to treat inflammatory bowel diseases. This patent discloses methods and compositions that utilize these peptide inhibitors to prevent or treat various diseases and disorders, including inflammatory bowel disease.

Career Highlights

Xiaoli Cheng has worked with notable companies such as Protagonist Therapeutics, Inc. and Protagonist Therapeutics, Inc. Her work has been instrumental in advancing therapeutic options for patients suffering from autoimmune conditions.

Collaborations

Xiaoli has collaborated with esteemed colleagues, including Ashok Bhandari and Gregory Thomas Bourne, contributing to a rich environment of innovation and research.

Conclusion

Xiaoli Cheng's innovative work in developing peptide inhibitors for autoimmune inflammation treatment showcases her dedication to advancing medical science. Her patents reflect a commitment to improving patient outcomes and addressing critical health challenges.